July 8th 2025
Patients with a single cardiometabolic disease have an approximate 48% greater risk of developing all-cause dementia compared with those without a cardiometabolic disease.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Harnessing the Potential of SGLT2 Inhibitors in Cardiorenal Metabolic Health: Strategies for Long-term Care an...
1.0 Credit / Cardiology, Endocrinology, Diabetes, & Metabolism, Nephrology
View More
Mastering Hypertrophic Cardiomyopathy: Cutting-Edge Therapies for Better Outcomes
1.5 Credits / Cardiology
View More
Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy
1.0 Credit / Cardiology
View More
Exploring Advances in the Management of DOAC-Associated Bleeding With Reversal Agents: Role of the Health-Syst...
1.5 Credits / Cardiology, Patient Safety
View More
Optimizing LDL-C Lowering and Adherence to Hyperlipidemia Guidelines
1.0 Credit / Cardiology
View More
Hyperlipidemia Overview and the Clinical and Economic Burden
1.0 Credit / Cardiology
View More
Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence
0.5 Credit / Cardiology
View More
The Role of the Pharmacist in the Management of Hyperlipidemia
1.0 Credit / Cardiology
View More
Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative
1.5 Credits / Cardiology
View More
The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies
1.5 Credits / Cardiology, Rare Diseases
View More
Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies
1.5 Credits / Pulmonology, Cardiology, Rare Diseases
View More
PBM Challenges and the Evolving Role of Oncology Pharmacists in Community Practices
0.75 Credit / Oncology, Law
View More
Advancing Stroke Prevention: The Pharmacist’s Role in Implementing the 2024 Guidelines
1.0 Credit / Cardiology
View More
The Role of IV Iron in Resolving Iron Deficiency in Heart Failure
1.0 Credit / Cardiology, Gastroenterology, General Pharmacy, Oncology, Women's Health
View More
From Guidelines to Practice: The Pharmacist’s Role in Chronic Heart Failure Therapy Optimization
1.5 Credits / Cardiology
View More
Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases
1.0 Credit / General Pharmacy, Law
View More
Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases (Pharmacy Technician Credit)
1.0 Credit / General Pharmacy, Law
View More
Identifying and Personalizing Iron Deficiency Anemia Treatment in Patients With Cancer
1.0 Credit / Cardiology, Gastroenterology, General Pharmacy, Oncology, Women's Health
View More
Managing Iron Replacement Therapies for Patients With Inflammatory Bowel Disease
1.0 Credit / Cardiology, Gastroenterology, General Pharmacy, Oncology, Women's Health
View More
Iron Deficiency Anemia Treatment Considerations in Women’s Health
1.0 Credit / Cardiology, Gastroenterology, General Pharmacy, Oncology, Women's Health
View More
Exploring ATTR Phenotypes and Identifying Appropriate Opportunities for Pharmacists to Intervene
1.0 Credits / Cardiology, Nephrology
View More
FDA OKs Dapagliflozin for Heart Failure With Reduced Ejection Fraction
May 6th 2020Officials with the FDA have approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with and without type 2 diabetes.